| 2.22 0.11 (5.21%) | 10-24 15:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.27 |
| Resists | First : | 2.4 | Second : | 2.8 |
| Pivot price | 2.08 |
|||
| Supports | First : | 1.67 | Second : | 1.22 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 1.99 |
| MA(100) : | 1.46 |
MA(250) : | 1.54  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 46.7 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 3.35 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABOS ] has closed below upper band by 26.9%. Bollinger Bands are 35.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.15 - 2.17 | 2.17 - 2.18 |
| Low: | 1.87 - 1.89 | 1.89 - 1.9 |
| Close: | 2.09 - 2.11 | 2.11 - 2.13 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Tue, 30 Sep 2025
Promising Penny Stocks To Watch In September 2025 - simplywall.st
Tue, 26 Aug 2025
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Thu, 14 Aug 2025
Acumen Pharmaceuticals stock maintains Buy rating at BTIG on promising Alzheimer’s drug - Investing.com
Tue, 12 Aug 2025
Earnings call transcript: Acumen Pharmaceuticals Q2 2025 sees EPS miss and stock dip - Investing.com
Tue, 12 Aug 2025
Acumen Pharmaceuticals’ Q2 2025 Financial and Strategic Update - TipRanks
Tue, 12 Aug 2025
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 67.8 (%) |
| Shares Short | 1,310 (K) |
| Shares Short P.Month | 1,410 (K) |
| EPS | -2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -75.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.06 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -118 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -0.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|